Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tulisokibart PK Study (Autoinjector vs Syringe)
NCT06575595Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tulisokibart in ulcerative colitis (UC) and Crohn's disease (3 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Curve from Time 0 to Infinity, Area Under the Curve from Time 0 to Last Measurable Concentration and 5 more. Started Sep 2024; status: completed.
02
Drugs
tulisokibart
03
Conditions
ulcerative colitis (UC)Crohn's disease
Beyond the preview
Go deeper on NCT06575595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575595.